Bioresearch Pharma S.A.

Manufacture of basic pharmaceutical products

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2024-03-14
Share capital
274,777.20 PLN
Activity description

Bioresearch Pharma is a company that repurposes existing topical drugs for dermatological applications, focusing on conditions such as androgenetic alopecia and psoriasis. They offer BRP-011, a therapy aimed at promoting hair growth, and BRP-007, a new treatment for plaque psoriasis with a unique mechanism of action. The company develops advanced medicines by utilizing well-tested therapeutic substances for new indications and creating novel drug formulations.

Registered address
ul. Zygmunta Glogera 2/11, 02-051 Warszawa, Poland
Email
Phone
Social media

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$0
Profit allocationLoss covered
Capital expenditure$991
Planned capital expenditure (next year)$12,557
Management board pay$50,176
Audit firmECOVIS Poland Sp. z o.o.

Filing timeliness

Financial statements were filed on time, on average 18 days early. All were audited by a statutory auditor.

  • 202524/06/2026
  • 202401/07/2025
  • 202327/06/2024
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Sector · Manufacturing20,175 / 24,570
Top 82%
City · Warszawa37,564 / 56,772
Top 66%
Voivodeship · Mazowieckie52,044 / 76,953
Top 68%
Country · Poland205,415 / 297,266
Top 69%

Results vs industry

Revenue
This companyUSD 76.29kMedianUSD 165.97kAverageUSD 2.30m
Net profit
This companyUSD -1.54mMedianUSD 1.32kAverageUSD 109.80k
Operating costs
This companyUSD 1.61mMedianUSD 201.81kAverageUSD 2.10m
Assets
This companyUSD 2.97mMedianUSD 118.27kAverageUSD 1.54m

Offer

  • Dermatology medicines
  • Anti-inflammatory medicines
  • Medicines for androgenetic alopecia

Website technology

Website
  • WordPress

Authorized Representatives

Łukasz Jarosław Zybaczyński age 63 – President of the Management Board
Katarzyna Koziak age 59 – Attorney-in-fact (joint)
Robert Litka age 55 – Management Board Member

Manner of representation

In the case of a one-person management board, the sole member of the management board is entitled to independently represent the company. In the case of a multi-member management board, representation of the company requires the joint action of two members of the management board or one member of the management board jointly with a commercial proxy.

Supervisory board

Paweł Augustyn age 66 – Supervisory Board Member
Bartosz Krzesiak age 42 – Supervisory Board Member
Mariusz Gujski age 57 – Supervisory Board Member
Jan Kospin age 42 – Supervisory Board Member
Maciej Tadeusz Wieloch age 50 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2022-03-09.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Mar 22, 2024Transformation

Public aid

PurposeGross amount
Aid for SMEs for innovation support
$1.5M

Competitors

Name
Goodwill Pharma Polska sp. z o.o.
Polmex Pharma Biniecki sp. k.
PNN Pharmaceuticals sp. z o.o. + limited partnership
Kosma Pharma Group sp. z o.o.
PRO Aktiv sp. z o.o.
Magnapharma sp. z o.o.
Histapharma sp. z o.o.
RED Pharma Laboratories Central Europe East sp. z o.o.
Emergopharm Holding sp. z o.o.
Ethifarm sp. z o.o.

Change history

DateEvent
2024-10-18Share capital increase
2024-05-07Share capital increase
2024-03-14Entered in the register

FAQ

Last updated: 2026-10-03